Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Neoplasm Metastasis 1Leukemia, Myeloid 1Graft vs Host Disease 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

pembrolizumab 12Radiotherapy 9avelumab 8Nivolumab 8cemiplimab 4Radiation 4Ipilimumab 4poly ICLC 3atezolizumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3talimogene laherparepvec 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Interferon-beta 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Cisplatin 2Carboplatin 2Biopsy 2veliparib 1vatalanib 1tremelimumab 1tocilizumab 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Merkel Cell × interferon gamma-1b × Clear all
NCT03747484 2025-03-06

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
7 enrolled 15 charts
Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡